Gossamer Bio (NASDAQ:GOSS) slumped 38% premarket on light volume in reaction to Novartis’ decision to terminate development of DP2 antagonist fevipiprant for asthma.
Gossamer’s lead candidate, GB001, also an DPS antagonist, is in Phase 2 development for rhinosinusitis and asthma.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.